First Manhattan CO Collegium Pharmaceutical, Inc Transaction History

First Manhattan CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 15, 2018	SELL	$14.16 - $24.3 $5,409 - $9,282	-382 Closed	0 $0
Q2 2018 Aug 01, 2018	BUY	$21.79 - $28.29 $4,161 - $5,403	191 Added 100.0%	382 $9,000
Q1 2018 Apr 20, 2018	SELL	$18.15 - $29.21 $8.46 Million - $13.6 Million	-466,009 Reduced 99.96%	191 $4,000
Q4 2017 Jan 22, 2018	BUY	$9.3 - $19.14 $4.34 Million - $8.92 Million	466,200	466,200 $8.61 Million

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.